Inscripta

Inscripta

A gene editing technology company founded in 2015 and based in Boulder, CO, USA.

Inscripta, founded in 2015 by Andrew Garst, Ryan T Gill and Tanya Lipscomb, provides gene editing tools for academic and commercial customers.In 2018 Inscripta acquired Solana Biosciences, a life sciences company founded by veterans of Illumina . Expansion plans include a new office in the life sciences hub of San Diego.

Inscripta has an enzyme engineering program rather than a particular application and they aim to provide tools for their customers to create their own applications faster.To tackle the lack of access and high cost of CRISPR gene-editing enzymes Inscripta is engineering CRISPR endonucleases called MADzymes.The DNA sequence for one MADzyme, MAD7 is provided free for any R&D use without reach-through royalty rights.MAD7 is derived from the genome of Eubacterium rectale and is a codon-optimized nuclease similar to Cpf1 (Cas12a). Inscripta is also engineering novel enzymes for exclusive use by industry partners.

Timeline

November 2020
Inscripta raises a $49,999,996 series D round from Korys.
December 10, 2019
Inscripta raises a $125,000,000 series D round from Paladin Capital Group.
April 4, 2019
Inscripta raises a $20,000,000 series C round from Foresite Capital, Merieux Developpement, NanoDimension, Paladin Capital Group and Venrock.
December 19, 2018
Inscripta raises a $30,000,000 series C round from Foresite Capital, Merieux Developpement, NanoDimension, Paladin Capital Group and Venrock.
February 28, 2018
Inscripta raises a $55,500,000 series C round from Foresite Capital, Merieux Developpement, NanoDimension, Paladin Capital Group and Spruce Capital Partners.
February 28, 2017
Inscripta raises a $23,000,000 series B round from Foresite Capital, NanoDimension, Spruce Capital Partners and Venrock.
April 1, 2016
Inscripta raises a $6,000,000 series A round.

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
Inscripta Series C round, April 2019
20,000,000
April 4, 2019
8 Results
Results per page:
Page 1 of 1

People

Name
Role
LinkedIn

Don Masquelier

VP Engineering

Erik Warnecke

VP Finance

Kevin Ness

CEO

Michael Graige

Chief Technical Officer

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Andrea Park
April 5, 2021
FierceBiotech
Inscripta just got another step closer to achieving its mission of bringing CRISPR gene editing technology to the scientific masses. The genomic engineering company, a member of Fierce Medtech's 2019 Fierce 15, recently closed a series E funding round totaling $150 million.

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.